- In May 2024, Nova Biomedical received FDA clearance for its Stat Profile Prime Plus analyzer, enhancing critical care diagnostic testing. This analyzer now supports micro-capillary sample mode, requiring only 90 microliters of capillary blood for an 11-test panel or 135 microliters for a 22-test profile
- In December 2022, Rutgers University and HeartSciences launched a multi-year collaboration to develop AI-based ECG algorithms to improve heart disease detection and expand the clinical value of an ECG for low-cost detection of heart disease
- In September 2022, Fitbit launched its three new fitness trackers, Fitbit Versa 4, Fitbit Sense 2 fitness watches, and the Fitbit Inspire 4 fitness tracker in India. All three models sport an improved design and promise to offer better performance. The wearables have a heart rate sensor, SpO2 monitor, stress monitor, and more
- In December 2021, Quest Diagnostics the nation's leading provider of diagnostic information services announced that it has acquired substantially all assets of Labtech Diagnostics, an independent clinical diagnostic laboratory provider serving physicians and patients primarily in South and North Carolina, Georgia and Florida. With the acquisition, Quest broadens access to diagnostic innovation and insights empowering better health for more communities in the Southeast
- In April 2020, Nova Biomedical announced the U.S. Food and Drug Administration (FDA) has cleared its Stat Profile Prime Plus critical care blood gas analyzer for point-of-care (POC) use. This clearance allows POC personnel to perform bedside critical care testing with lab-quality results in as little as one minute. Prime Plus features maintenance-free sensor technology to provide 19 essential critical care tests including blood gases, electrolytes, metabolites, hematology, and co-oximetry, providing clinicians with a rapid, detailed diagnostic profile, including a comprehensive metabolic panel
